REGN: third_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/0f06af2f-d57a-447e-9285-92adcb2a5c9c/","filing_uuid":"0f06af2f-d57a-447e-9285-92adcb2a5c9c","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/0f06af2f-d57a-447e-9285-92adcb2a5c9c/print/","filing_document_content_type":"text/html","income":"10000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Eugenia Edwards Pierson","dt_posted":"2026-10-19T14:14:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 Massachusetts Ave. NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":4301,"url":"https://lda.gov/api/v1/registrants/4301/","house_registrant_id":31381,"name":"ARNOLD & PORTER KAYE SCHOLER LLP","description":"Law firm","address_1":"601 Massachusetts Ave. NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NICHOLAS TOWNSEND","contact_telephone":"+1 202-942-5249","dt_updated":"2026-07-30T11:53:37.108571-04:00"},"client":{"id":210738,"url":"https://lda.gov/api/v1/clients/210738/","client_id":1005305,"name":"REGENERON PHARMACEUTICALS, INC.","general_description":"Biopharmaceutical development and manufacturing","client_government_entity":false,"client_self_select":null,"state":"NY","state_display":"New York","country":"US","country_display":"United States of America","ppb_state":"NY","ppb_state_display":"New York","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-06-07"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Outreach related to drug pricing policies, including patent and intellectual property issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140808,"prefix":null,"prefix_display":null,"first_name":"SONJA","nickname":null,"middle_name":null,"last_name":"NESBIT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":63646,"prefix":null,"prefix_display":null,"first_name":"EUGENIA","nickname":null,"middle_name":null,"last_name":"PIERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":102193,"prefix":null,"prefix_display":null,"first_name":"BOBBY","nickname":null,"middle_name":null,"last_name":"MCMILLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}